ERBB2 and triple-negative breast carcinoma: Personalized NAC can optimize treatment outcomes, achieving a high clinical response rate (approximately 80%) and a pathological complete response (pCR) in 6–25% of BC patients [10,11], with even higher rates (>50%) in HER2-positive and triple-negative breast cancer (TNBC) subtypes treated with anti-HER2 agents and immune checkpoint inhibitors, respectively [12,13].